Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (NLTX) Stock Overview

Explore Neoleukin Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NLTX●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$3.49
$0.05(1.45%)
U.S. Market is Open · 13:57

Neoleukin Therapeutics, Inc. (NLTX)

Meyka AI Score

Z

Key Financials

Market Cap8.2M
P/E Ratio-4.42
EPS (TTM)$-12.28
ROE-0.45%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

NLTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Neoleukin Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NLTX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $N/A for the NASDAQ listing.

Key metrics behind Neoleukin Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.42 and a market capitalization of 8.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of NLTX on the NASDAQ.

Price Performance (NASDAQ: NLTX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
-74.64%
3-Month Change
-75.49%
6-Month Change
-81.14%
Year-to-Date (YTD) Change
N/A
1-Year Change
-69.39%
3-Year Change
-98.71%
5-Year Change
-92.61%
All-Time (Max) Change
-98.54%

Contact Information

https://www.germfalcon.com
855 226 6447
188 East Blaine Street, Seattle, WA, 98102

Company Facts

70 Employees
IPO DateMar 7, 2014
CountryUS

Frequently Asked Questions